je.st
news
Tag: announces study
NASEM announces provisional committee for new study on life cycle analyses of low-carbon fuels
2021-05-01 10:55:39| Green Car Congress
Tags: life
study
committee
cycle
Trevena Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain
2015-09-02 07:04:14| drugdiscoveryonline News Articles
Trevena, Inc., a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), recently announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery
Tags: results
study
positive
phase
Merck Announces Phase 3 Study of Single-Dose EMEND (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
2015-06-29 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Mercks substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC). Language: English Contact: MerckMedia:Doris Li, 908-740-1903orAn Phan, 908-255-6325orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Aimmune Therapeutics Announces Positive Phase 2 Study Results Of AR101 For The Treatment Of Peanut Allergy
2015-06-17 06:39:17| foodingredientsonline Home Page
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced recently that a Phase 2 study (ARC001) evaluating the company’s lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively
Tags: of
results
study
positive
Enanta Announces SVR12 Results Of 95% From AbbVie's GIFT-1 Study In Non-Cirrhotic, Japanese Patients With Genotype 1b Hepatitis C Virus1
2015-06-03 06:35:57| drugdiscoveryonline Home Page
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced recently that new data from AbbVie’s phase 3 GIFT-I study, its investigational, all-oral, interferon (IFN)- and ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir, was presented at the Annual Meeting of the Japan Society of Hepatology in Kumamoto, Japan
Tags: c
results
study
japanese